EQT.
EQT's India franchise is trading a record fundraise for an unresolved exit: BPEA IX closed at $15.6bn in April 2026 while the firm's largest India ticket, CitiusTech, sits below its own asking price in a stalled sale process.
GW GP Score
EQT Private Capital Asia is the renamed continuation of Baring Private Equity Asia, founded by Jean Eric Salata in 1997 as a Barings Bank affiliate, spun out via management buyout in 2000, and folded into EQT through an all-share combination completed in October 2022. The India desk Salata's successor, Hari Gopalakrishnan, has run since 2007 is now central to the group's own succession: Gopalakrishnan became co-head of the whole Asia private equity platform in May 2026, the same month Salata was nominated to chair EQT's global board. Operationally the desk is mid-rotation inside India healthcare RCM: it paid ChrysCapital over $850M (~17x EBITDA) for GeBBS Healthcare Solutions in Sep 2024, then sold AGS Health, the asset GeBBS effectively replaces on its book, to Blackstone for $1.4bn in Aug 2025 - a ~4.4x headline multiple on the ~$320M paid for it in 2019, unadjusted for follow-on capital (E). The strain point is CitiusTech: EQT mandated JPMorgan in Dec 2025 to sell its remaining 40% stake at a $2-2.5bn valuation, and by Mar 2026 binding bids from Advent, PAG, CVC and TA Associates were running 15-40% below that ask at $1.5-1.7bn. Two older holds show the playbook can work at listed scale: the 2015-2024 CMS Info Systems hold (EBITDA up roughly 3x, accelerating to a 34% CAGR in its final two years before a full block-trade exit) and Sagility, carved out of Hinduja Global Solutions for $1.2bn in Jan 2022, listed on the NSE in Nov 2024, then sold down twice more in 2025 for a combined ~₹8,400 Cr while EQT still holds roughly 51% of a company now marked near ₹21,900 Cr. Whether CitiusTech clears $2bn-plus, and whether Indira IVF's SEBI-approved but still-unlisted IPO actually prices, are the two swing factors for the franchise's realised return this cycle.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
CitiusTech's 40% stake sale: whether a buyer emerges near EQT's $2-2.5bn ask or the price settles closer to the $1.5-1.7bn bids reported in Mar 2026.
Indira IVF's SEBI-approved IPO: whether it actually lists in 2026 and at what valuation against the ₹20,000-25,000 Cr talk reported in Jul 2025.
Sagility B.V. has sold down twice in 2025 alone (May OFS, Nov block) after the Nov 2024 IPO; shares fell on both announcements, and a platform three tranches into a realisation programme is one further block away from losing control (~51% held as of Nov 2025).
Computed from current dossier sources; analyst override pending.
A score of 74 reflects a franchise with four real or partial cash realisations in the window (AGS Health, O2 Power, CMS, and Sagility's multi-tranche sell-down) and unmatched regional fundraising scale (BPEA IX's $15.6bn hard cap) sitting against two unresolved swing factors: the CitiusTech stake sale and the Indira IVF listing. Either could move the mark by several points once priced.
Graded underPrivate equity rubric v1.0→CitiusTech booked $427.6M FY25 revenue, GeBBS was bought at ~17x EBITDA, Sagility's EBITDA more than doubled since its 2022 carve-out, Indira IVF runs 116 centres; majority/control at 5 of 8 positions, but CitiusTech - the largest ticket - is down to a 40% co-invest stake
AGS Health ($1.4bn, Aug 2025), O2 Power ($1.5bn full exit, Apr 2025) and CMS Info Systems (full block exit, Feb 2024) are real cash returns; Sagility's ~₹8,400 Cr multi-tranche partial realisation adds a fourth; CitiusTech's stalled 40% sale (bids 15-40% under ask, Mar 2026) is the one unresolved drag
O2 Power was built to 4.7GW from zero, Sagility's EBITDA more than doubled and CMS's EBITDA CAGR accelerated to 34% in its final two years - genuine operating improvement; GeBBS (~17x EBITDA) and HDFC Credila ($1.11bn price vs $250M primary injection) were both priced for growth already embedded
BPEA IX's $15.6bn hard cap and 75+ new investors show strong LP demand, but the fund was only 5-10% deployed at close and GeBBS was bought at a rich ~17x EBITDA multiple
Gopalakrishnan has run India since 2007 and added the Asia co-head role in May 2026; Salata is set to chair EQT Group at the same AGM; fund sizes have stepped up every vintage since the 2022 merger, with CPP Investments among the re-up LPs
Asset quality & control 25% · Exit realisation 30% · Value creation 15% · Capital discipline 15% · Franchise stability 15% — the five contributions above sum to 74. Raw scores compare within private equity; across cohorts compare the tier. See the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
Indira IVF liquidity clears with credible OFS/block-sale evidence.
Indira IVF's SEBI-approved IPO: whether it actually lists in 2026 and at what valuation against the ₹20,000-25,000 Cr talk reported in Jul 2025.
CitiusTech's 40% stake sale: whether a buyer emerges near EQT's $2-2.5bn ask or the price settles closer to the $1.5-1.7bn bids reported in Mar 2026.
GeBBS-for-AGS-Health is the trade to underwrite carefully: EQT re-bought the same India healthcare-RCM thesis at ~17x EBITDA a year after selling the asset it displaces for $1.4bn - ask whether that is conviction or a rich re-entry. Sagility is the cleaner diligence file: an EBITDA that more than doubled off a distressed carve-out, and ~₹8,400 Cr already banked while EQT still owns roughly half.
Sagility B.V. has sold down twice in 2025 alone (May OFS, Nov block) after the Nov 2024 IPO; shares fell on both announcements, and a platform three tranches into a realisation programme is one further block away from losing control (~51% held as of Nov 2025).
CitiusTech's 40% stake sale: whether a buyer emerges near EQT's $2-2.5bn ask or the price settles closer to the $1.5-1.7bn bids reported in Mar 2026.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 0 pressure catalyst(s); top driver: monthly refresh only.
The funds
BPEA IX: $14.9bn fee-generating of $15.6bn committed (Apr 2026); ~$35bn raised across live vintages since 2018 (E) across 5 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| BPEA Private Equity Fund IX | 2026AI repricing | $15.6bn | Large-cap buyout | Hard-cap close Apr 2026, largest-ever Asia-Pacific PE fund; only 5-10% deployed at close per EQT |
| EQT Private Capital Asia Mid-Market Growth Partnership | 2023Trough window | $1.6bn | Mid-market growth buyout | Closed at 2x its $750M target (May 2024); vehicle behind Indium Software (2023) and IndoStar Home Finance (2024) |
| BPEA Private Equity Fund VIII | 2022Correction onset | $11.2bn | Large-cap buyout | Backed HDFC Credila (2023, w/ ChrysCapital) and GeBBS Healthcare Solutions (2024); ~70-75% invested at the GeBBS close per EQT |
| BPEA Private Equity Fund VII | 2018Expansion | $6.54bn | Large-cap buyout | Backed AIG Hospitals (2022) and the since-exited AGS Health (2019); fully invested |
| BPEA Private Equity Fund VI | 2015First boom | $3.99bn | Large-cap buyout | Backed the 2015 CMS Info Systems entry, exited in full via block trade Feb 2024 |
Closest booksBain Capital (1 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Latest vehicle closed inside the current exit/repricing window.
Next liquidityIndira IVF
5 visible exit events since Jul 2024.
Latest vehicle closed inside the current exit/repricing window.
4 up / 3 flat / 1 down tracked signals.
No senior departure flagged in key people.
4 up / 3 flat / 1 down
5 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Marked overhangCitiusTech: names with negative 12-month mark or momentum signals in the reconstructed book.
Barbell market: AI premium vs everything else
Best entry conditions of the cycle
Repricing began mid-deployment
Rational growth vintages
116 fertility centres across 20 states; SEBI approved a ₹3,500 Cr OFS-only IPO Dec 2025, not yet listed as of Sep 2026 after a Mar 2025 withdrawal
At least one cited source is dated 2026.
7 visible events tracked.
8 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 3 · +2
Peer median 2 · -1
Peer median 89 · -4
Peer median 38 · +0
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
The dossier is current and has near-term liquidity or fund events that can change the view quickly.
Current · At least one cited source is dated 2026.
CitiusTech's 40% stake sale: whether a buyer emerges near EQT's $2-2.5bn ask or the price settles closer to the $1.5-1.7bn bids reported in Mar 2026.
Refresh after each filing, listing, OFS, first close, final close or partner announcement.
Indira IVF's SEBI-approved IPO: whether it actually lists in 2026 and at what valuation against the ₹20,000-25,000 Cr talk reported in Jul 2025.
Indira IVF: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
No major evidence gap flagged.
29 total sources · 59% primary
At least one cited source is dated 2026.
EQT: BPEA IX closes at $15.6bn hard cap (Apr 2026)
Maintain monthly source check; escalate on fund close, DRHP, OFS, block sale or senior-partner change.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
Eight live India platforms tracked below, spanning healthcare RCM/services (including one listed multi-tranche realisation), fintech NBFC carve-outs and one mid-market tech-services buyout.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Sagility India | Healthcare | 2022 | Carve-out buyout ($1.2bn EV, from Hinduja Global Solutions) | Public | ▲ | NSE-listed Nov 2024 (₹2,106 Cr OFS); two further 2025 sell-downs (May OFS 15.02%, Nov block 16.4%) banked ~₹8,400 Cr total while Sagility B.V.'s holding fell from 97% to about 51%; EBITDA more than doubled since the carve-out per EQT |
| CitiusTech | Healthcare | 2019 | 80% control ($1bn EV); down to 40% after the 2022 Bain Capital tranche | Private | ▼ | Healthcare-focused IT/BPO services provider, mapped to Healthcare over SaaS & Dev Tools given its client base; 40% stake in an active, unresolved sale process since Dec 2025 |
| GeBBS Healthcare Solutions | Healthcare | 2024 | Control stake (from ChrysCapital, ~17x EBITDA) | Private | → | Bought Sep 2024 for >$850M via Fund VIII; US-headquartered with major India delivery operations |
| AIG Hospitals | Healthcare | 2022 | Minority (from Samara Capital) | Private | ▲ | Hyderabad gastroenterology hospital platform, ~1,000 tertiary-care beds; Fund VII |
| Indira IVF | Healthcare | 2023 | 60% control (₹6,000 Cr) | Private | → | 116 fertility centres across 20 states; SEBI approved a ₹3,500 Cr OFS-only IPO Dec 2025, not yet listed as of Sep 2026 after a Mar 2025 withdrawal |
| HDFC Credila | Fintech | 2023 | 90% buyout w/ ChrysCapital ($1.11bn + $250M growth capital) | Private | ▲ | Education-loan NBFC carve-out from HDFC; India's largest-ever PE financial-services buyout |
| IndoStar Home Finance (Niwas) | Fintech | 2024 | 100% carve-out (₹1,750 Cr + ₹500 Cr growth capital) | Private | ▲ | Affordable housing finance in Tier II-IV cities; signed Sep 2024, RBI-approved Mar 2025, closed Jul 2025 via Mid-Market Growth Partnership |
| Indium Software | SaaS & Dev Tools | 2023 | Majority (Mid-Market Growth Partnership) | Private | → | Chennai digital-engineering and QA services firm; signed Dec 2023, expected close Q1 2024 |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
The last two India platform moves are a swap inside the same RCM subsector, not a new bet: EQT paid ChrysCapital over $850M (~17x EBITDA) for GeBBS in Sep 2024, then sold AGS Health - the asset GeBBS effectively replaces on the book - to Blackstone for $1.4bn a year later. Everything else on the sheet predates that swap: HDFC Credila's $1.11bn NBFC carve-out (Jun 2023, w/ ChrysCapital), Indira IVF's ₹6,000 Cr majority buy (Jul 2023), and the two Mid-Market Growth Partnership tickets, Indium Software (Dec 2023) and IndoStar Home Finance (signed Sep 2024, closed Jul 2025). No new India platform has been announced since GeBBS.
From ChrysCapital, via Fund VIII
Closed Jul 2025 after RBI approval
Realisation · are LPs getting paid?
Four cash-realisation events sit in the file, one still running: AGS Health to Blackstone for $1.4bn (Aug 2025), O2 Power's full $1.5bn sale to JSW Neo Energy (Apr 2025, EQT's first Asia infrastructure realisation) and the Feb 2024 CMS Info Systems block-trade after a 3x-EBITDA, nine-year hold are complete. Sagility India is the partial pattern: an IPO plus two 2025 sell-downs banked ~₹8,400 Cr (~$1bn) while EQT still controls roughly 51% of a company the market now marks near ₹21,900 Cr - value created and partly cashed, not fully surrendered. The open question is CitiusTech, EQT's largest India ticket: a sale process it started in Dec 2025 had, by Mar 2026, drawn binding bids of $1.5-1.7bn against its own $2-2.5bn ask - a 15-40% gap still unresolved as of this vintage.
Sold to Blackstone for $1.4bn (earlier reports through the process ranged $1.1-1.6bn; MarketScreener's closing report is the reconciled figure used here), from Fund VII; entered 2019 at ~$320M - a ~4.4x headline multiple on the reconciled price, unadjusted for follow-on capital (E).
Sagility B.V. sold 16.4% (76.9 Cr shares) at ₹47.6 for ₹3,660 Cr (14 Nov 2025); promoter holding fell from ~67% to about 51%, retaining control.
SEBI minimum-public-shareholding OFS: 15.02% sold for ~$315M (27-28 May 2025); holding fell from ~83% (post-IPO) to ~67%.
EQT Infrastructure IV and Temasek sold the 4.7GW renewable platform (built from zero since 2020) whole to JSW Neo Energy for $1.5bn (₹12,468 Cr); EQT's first Asia-Pacific infrastructure exit, signed Dec 2024 and completed Apr 2025 - a different fund lineage (EQT Infrastructure, not BPEA/Asia PE) but the same India franchise.
₹2,106 Cr all-OFS listing on NSE/BSE (5-7 Nov 2024), priced ₹28-30; Sagility B.V.'s holding fell from 97% to about 83%; ~3.2x oversubscribed.
Sion Investments (Fund VI) sold the remaining 26.7% for a $187M block trade, completing a full exit after EBITDA compounded ~3x - accelerating to a 34% CAGR - over the 2015-2024 hold.
Pre-merger BPEA sold Hexaware to Carlyle's CA Magnum Holdings for ~$3bn EV, after delisting it from Indian exchanges in 2020; Carlyle re-listed it via a $1bn IPO in Feb 2025.
Hard cap, Apr 2026, up from Fund VIII's $11.2bn (2022); 75+ new investors incl. a $700M CPP Investments commitment
IPO (Nov 2024) + two OFS/block tranches (May, Nov 2025); still holds ~51% at a ₹21,918 Cr market cap (4 Sep 2026)
Binding bids received Mar 2026 for EQT's 40% stake sit 15-40% below its own target range
9-year hold, EBITDA growth accelerating to a 34% CAGR in the final two years before a full block-sale exit
Per EQT's own disclosure at the Apr 2026 hard-cap close
BPEA IX's $15.6bn hard-cap close (Apr 2026, up from Fund VIII's $11.2bn in 2022) is the clearest external vote of confidence, with CPP Investments alone committing $700M. Set against EQT's own disclosure that the fund was only 5-10% deployed at close, and the CitiusTech bid-ask gap, the raise reads more as LP appetite for Asia buyout exposure generally than proof of EQT India's near-term realised performance. E.
What they're doing
Buys control or majority stakes in mid-to-large India services and healthcare platforms, often via carve-outs from strategic or financial parents (HDFC, IndoStar, ChrysCapital) rather than founder-led auctions.
Uses the 2023-vintage $1.6bn Mid-Market Growth Partnership as the India entry vehicle for sub-$300M tickets (IndoStar, Indium), reserving the flagship BPEA fund for control buyouts above $500M.
Runs a repeatable governance playbook through a small operating-partner bench: Jimmy Mahtani has sat on CMS, CitiusTech, Hexaware and AGS Health boards concurrently.
Exits through trade sales, block trades and its own IPOs alike: strategic sales for CMS/AGS Health/Hexaware, but Sagility (a 2022 carve-out, not a founder-retained business) was taken public in Nov 2024 and harvested in two further 2025 block sales while EQT kept control - the same listed-harvest route now queued for Indira IVF.
What can break
Sagility B.V. has sold down twice in 2025 alone (May OFS, Nov block) after the Nov 2024 IPO; shares fell on both announcements, and a platform three tranches into a realisation programme is one further block away from losing control (~51% held as of Nov 2025).
CitiusTech's 40% stake sale is testing EQT's own $2-2.5bn ask against binding bids of $1.5-1.7bn (Mar 2026); a close below ask marks down the return on its largest India healthcare-tech position.
BPEA IX closed at its $15.6bn hard cap only 5-10% deployed (Apr 2026): most of the region's committed capital, India included, is still unspent into a market where GeBBS-style assets are trading near 17x EBITDA.
Indira IVF's IPO was withdrawn once already (Mar 2025, over concerns tied to a biopic of the founder); SEBI approval (Dec 2025) had not converted into a listing as of Sep 2026.
Leadership is consolidating at the top in the same year as the largest-ever fundraise: Hari Gopalakrishnan added the Asia co-head role in May 2026 on top of running India, and BPEA founder Jean Eric Salata is due to become EQT Group's chairperson at the same AGM.
GeBBS was bought at ~17x EBITDA (Sep 2024, GW estimate from the disclosed >$850M price): a rich entry that raises the operating bar for a clean exit.
CitiusTech's 40% stake sale: whether a buyer emerges near EQT's $2-2.5bn ask or the price settles closer to the $1.5-1.7bn bids reported in Mar 2026.
Indira IVF's SEBI-approved IPO: whether it actually lists in 2026 and at what valuation against the ₹20,000-25,000 Cr talk reported in Jul 2025.
Whether Sagility B.V.'s ~51% holding falls further: two sell-downs within 2025 alone (May, Nov) read as a standing programme, not a one-off.
BPEA IX deployment pace off a 5-10%-invested base at its Apr 2026 hard-cap close.
Whether GeBBS's ~17x EBITDA entry (Sep 2024) is validated once the AGS Health-vacated RCM book folds into the same thesis.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
GeBBS-for-AGS-Health is the trade to underwrite carefully: EQT re-bought the same India healthcare-RCM thesis at ~17x EBITDA a year after selling the asset it displaces for $1.4bn - ask whether that is conviction or a rich re-entry. Sagility is the cleaner diligence file: an EBITDA that more than doubled off a distressed carve-out, and ~₹8,400 Cr already banked while EQT still owns roughly half.
Sagility's carve-out-to-IPO-to-sell-down arc (Hinduja 2022, NSE listing Nov 2024, two 2025 block sales) is now the desk's template alongside CMS and Hexaware: distressed or non-core India services units, built up, taken public, harvested in tranches rather than sold whole. Expect EQT to keep hunting corporate carve-outs over founder auctions.
CitiusTech's bid-ask gap ($1.5-1.7bn vs $2-2.5bn) is the cleanest published marker of how far healthcare-tech multiples have compressed since 2022. Watch Indira IVF's IPO as the next read: a ₹3,500 Cr all-secondary listing prices India's IVF category for the first time.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.